US Re-engages GAVI Funding
Analysis based on 20 articles · First reported Jun 02, 2026 · Last updated Jun 09, 2026
The re-engagement of the United States>>> with GAVI>>> is expected to positively impact the global health sector, particularly pharmaceutical and biotechnology companies involved in vaccine development and distribution. The release of $600 million in previously withheld funds will provide a significant boost to GAVI>>>'s operations, enabling it to expand its vaccine programs and respond more effectively to outbreaks like Ebola, potentially increasing demand for related medical supplies and services.
The United States>>>, through Secretary of State Marco Rubio>>>, announced its decision to re-engage with GAVI>>>, the global vaccine alliance, after the Donald Trump>>> administration, influenced by Health Secretary Robert F. Kennedy Jr.>>>, had previously pulled and withheld significant funding. This re-engagement comes amid an Ebola outbreak in the Democratic Republic of the Congo>>> and Uganda>>> and is aimed at resolving the dispute over vaccine safety concerns, particularly regarding the preservative Thiomersal. GAVI>>>'s chief executive, Sania Nishtar>>>, welcomed the news, emphasizing the importance of unlocking congressional funds to maintain global health security. The United States — United States Department of Health and Human Services>>> and State Department are now in discussions with GAVI>>> to find a constructive path forward, with GAVI>>> having already approved a strategy to phase out vaccines containing Thiomersal.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard